The FDA reportedly based its decision to authorize doses 4 and 5 on Israeli data posted on the preprint server medRxiv, February 15, 2022. Story at-a-glance A preprint study posted April 3, 2022, reports high rates of infection with BA.1, BA.1.1 and BA.2 — variants of Omicron — among triple-jabbed health care workers. In all, the incidence rate among the triple-jabbed with one of these variants was 22%, and only 10% remained asymptomatic March 29, 2022, the U.S. Food and Drug Administration authorized a second booster (dose No. 4, for those taking Pfizer or Moderna) for adults over age 50, as well as a third booster (dose No. 5) for immunocompromised people aged 12 and older. The additional boosters are to be given four months after the last dose The U.S. Centers for Disease Control and Prevention is also recommending adults who have received two doses of Janssen’s viral vector …